Drug Interactions between mitotane and Recorlev
This report displays the potential drug interactions for the following 2 drugs:
- mitotane
- Recorlev (levoketoconazole)
Interactions between your drugs
mitotane levoketoconazole
Applies to: mitotane and Recorlev (levoketoconazole)
GENERALLY AVOID: The concomitant administration of strong CYP450 3A4 inducers may significantly reduce levoketoconazole serum levels. There are no data about the interaction between strong CYP450 3A4 inducers and levoketoconazole. However, there are data for ketoconazole, of which levoketoconazole is an enantiomer. When ketoconazole 400 mg/day was coadministered with the strong CYP450 3A4 inducer nevirapine 200 mg/day for 14 days, followed by 400 mg/day for 14 days, the area under the concentration-time curve (AUC) of ketoconazole decreased by an average of 72% and the maximum plasma concentration (Cmax) decreased by 44%. Nevirapine plasma AUCs increased by 15% to 28%, which is not considered clinically significant. The mechanism appears to be enhanced first-pass metabolism and hepatic enzyme metabolism (CYP450 3A4) of the azole agent.
MANAGEMENT: Levoketoconazole manufacturer recommends avoiding concomitant therapy with potent CYP450 3A4 inducers from 2 weeks before and during treatment with levoketoconazole.
References (4)
- (2019) "Product Information. Ketoconazole (ketoconazole)." Mylan Pharmaceuticals Inc
- (2022) "Product Information. Recorlev (levoketoconazole)." Xeris Pharmaceuticals Inc
- Auchus R, Pivonello R, Fleseriu M, et al. (2022) Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. https://www.tandfonline.com/doi/pdf/10.1080/17446651.2021.1945440
- (2022) "Product Information. Viramune (nevirapine)." Boehringer Ingelheim
Drug and food interactions
mitotane food
Applies to: mitotane
ADJUST DOSING INTERVAL: Fat-rich food enhances the absorption of mitotane. One study evaluated blood levels of mitotane (o,p'-DDD) after subjects ingested a single dose of 2 g administered using various delivery vehicles (e.g., tablets, granules, milk, chocolate or oil emulsion). Mitotane plasma levels were significantly higher for milk, chocolate, and oil emulsion when compared to those who received tablets or granules alone. In the same study, mitotane levels were evaluated in subjects following long-term treatment (total dose of 200 g over 30 to 60 days) in tablet, oil emulsion, or milk formulations. Significantly higher mean plasma levels were recorded in subjects who received mitotane as an oil emulsion or mixed in milk, when compared to tablets alone. Additionally, the recovery of o,p'-DDD from the feces was about 5 times higher in subjects who received tablets alone, suggesting absorption was reduced when compared to subjects who received mitotane mixed with a fat-rich vehicle (e.g., oil emulsion or milk).
GENERALLY AVOID: Concomitant use of mitotane with central nervous system (CNS) depressants, including alcohol, may potentiate adverse effects such as somnolence and sedation.
MANAGEMENT: According to product labeling, mitotane tablets should be taken during meals containing fat-rich food (e.g., milk, chocolate, or oil) and with a full glass of water. Patients should be advised to avoid or limit consumption of alcohol and to avoid activities requiring mental alertness such as driving or operating hazardous machinery until they know how the medication affects them.
References (4)
- (2023) "Product Information. Lysodren (mitotane)." HRA Pharma America
- (2023) "Product Information. Lysodren (mitotane)." Medunik Canada
- (2023) "Product Information. Lysodren (mitotane)." HRA Pharma UK & Ireland Ltd
- Moolenaar AJ, van Slooten H, van Seters AP, Smeenk D (2023) Blood levels of o,p-DDD following administration in various vehicles after a single dose and during long-term treatment https://link.springer.com/article/10.1007/BF00258213
levoketoconazole food
Applies to: Recorlev (levoketoconazole)
GENERALLY AVOID: Excessive use of alcohol or products containing alcohol together with ketoconazole or levoketoconazole may potentiate the risk of liver injury. Serious hepatotoxicity has been reported with levoketoconazole. Hepatotoxicity requiring liver transplantation has been reported with the use of oral ketoconazole, of which levoketoconazole is an enantiomer. Some patients had no obvious risk factors for liver disease. In addition, use of alcohol or products containing alcohol during ketoconazole or levoketoconazole therapy may result in a disulfiram-like reaction in some patients. Symptoms of disulfiram-like reaction include flushing, rash, peripheral edema, nausea, and headache.
GENERALLY AVOID: Coadministration with grapefruit juice may increase the plasma concentrations of ketoconazole or levoketoconazole. The mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. Inhibition of hepatic CYP450 3A4 may also contribute. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.
When administered to healthy volunteers with a high-fat meal (875 calories; 62% fat), levoketoconazole systemic exposure (AUC) increased by 30% while peak plasma concentration (Cmax) did not change and the time to reach Cmax (Tmax) was delayed from 2 to 4 hours, compared to fasted conditions.
MANAGEMENT: Levoketoconazole may be administered with or without food. Excessive consumption of alcohol should generally be avoided during ketoconazole or levoketoconazole therapy. Patients should preferably avoid or limit consumption of grapefruit, grapefruit juice, or any supplement containing grapefruit extract during ketoconazole or levoketoconazole therapy. Patients receiving ketoconazole or levoketoconazole should be instructed to contact their doctor immediately if they experience swelling, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage.
References (4)
- (2019) "Product Information. Ketoconazole (ketoconazole)." Mylan Pharmaceuticals Inc
- (2022) "Product Information. Recorlev (levoketoconazole)." Xeris Pharmaceuticals Inc
- Auchus R, Pivonello R, Fleseriu M, et al. (2022) Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. https://www.tandfonline.com/doi/pdf/10.1080/17446651.2021.1945440
- (2021) "Product Information. Ketoconazole (ketoconazole)." Burel Pharmaceuticals Inc
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Adrenal corticosteroid inhibitors
Therapeutic duplication
The recommended maximum number of medicines in the 'adrenal corticosteroid inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'adrenal corticosteroid inhibitors' category:
- mitotane
- Recorlev (levoketoconazole)
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.